An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Moderate Hepatic Impairment
Latest Information Update: 12 Jun 2025
At a glance
- Drugs Opevesostat (Primary) ; Fludrocortisone; Prednisone
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 05 Jun 2025 Planned End Date changed from 12 Aug 2025 to 26 Aug 2025.
- 05 Jun 2025 Planned primary completion date changed from 5 Aug 2025 to 19 Aug 2025.
- 16 May 2025 Planned initiation date (estimated date for recruitment of the first subject) changed to 16 May 2025.